Technical Summary for NEU:

Price action strength has been developing over the past 10 to 15 sessions. Longer term directional characteristics indicate bullishness. A well established uptrend is underway. The last 2 weeks are showing increasing amounts of bullish volume. Prices have been successively closing up, especially in recent sessions. The last session was bullish. Average session trading value is insufficient and will lead to entry and exit liquidity issues. Not recommmended to trade this instrument. Sortino Ratio indicates lowered risk. (2.98) AGL Ratio indicates positive expectancy. (1.04) Overall Market Index (^AORD) is trending Bullish - Strong.

Deep Research for NEU:

Possible news-related drivers for NEU.AX’s recent 10‑session uptrend

- Strong DAYBUE (trofinetide) sales / positive Q1 update: Acadia reported DAYBUE Q1 net sales of US$101m (up ~20% year‑on‑year); Neuren reported this translated to higher Q1 royalty income and highlighted >250 prescriptions for the new DAYBUE STIX powder formulation. That Q1 sales/launch messaging is repeatedly cited in market reports as a direct catalyst for share gains.

- Launch and broader rollout of DAYBUE STIX (new powder formulation): FDA approval and a limited Q1 2026 launch (then broader availability in early April 2026) and strong early patient / caregiver feedback increase the revenue growth story and investor confidence.

- Upward royalties / positive financials and guidance linkage: Neuren’s FY2025 results showed growing royalty income (A$65m) and a strong cash position; Acadia reaffirmed FY2026 DAYBUE net‑sales guidance (US$460–490m), implying higher full‑year royalties to Neuren. Those numbers and the implied royalty outlook are frequently cited by market commentary when explaining upward price moves.

- Share buy‑back activity and capital management: Completion of a A$50m on‑market buy‑back in 2025 and announcement of a new buy‑back (commencing March 2026) supports demand for stock and signals board belief the shares were undervalued — a common positive catalyst for prices.

- Clinical and pipeline milestones: Advancement of NNZ‑2591 (Koala Phase 3 commenced for Phelan‑McDermid syndrome, Fast Track designations, new patent to 2040) materially improves the company’s growth optionality and can raise speculative / strategic interest from investors.

- Visibility / corporate communications and market mechanics: Frequent ASX announcements (earnings, Q1 highlights, conference participation, investor hub material), temporary trading pauses ahead of material releases, and consequent media/retail discussion raise investor attention and can amplify moves when the news is positive.

Notes and caveats

- The items above are the principal, news‑based explanations identifiable from company filings and market coverage over the past few months; other non‑news factors (broader biotech sector flows, analyst adjustments, block‑trades or large institutional buying, and retail/social amplification) may also contribute to short‑term trends.

- Sources: Neuren/ASX releases and market coverage cited above.

Analysis Date: 2026/08/01